Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma

Helen H.W Chen, Sen-Tien Tsai, Mei Shu Wang, Yuan-Hua Wu, Wei-Ting Hsueh, Ming-Wei Yang, I. Chun Yeh, Jin Ching Lin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC. Methods and Materials: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72%) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications. Results: All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences-3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively. There were no Grade 4 acute or chronic radiation-related complications. Conclusions: Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications.

Original languageEnglish
Pages (from-to)1408-1414
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue number5
DOIs
Publication statusPublished - 2006 Dec 1

Fingerprint

acceleration (physics)
radiation therapy
Radiotherapy
cancer
Neck
Nasopharynx
Survival
metastasis
chemotherapy
toxicity
Cisplatin
Nasopharyngeal carcinoma
grade
tumors
Radiation
Neoplasm Metastasis
Recurrence
Drug Therapy
dosage
radiation

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{3f18cc4f7b7849fab4e726e7744b1ba4,
title = "Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma",
abstract = "Purpose: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC. Methods and Materials: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72{\%}) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications. Results: All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences-3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1{\%}, regional control 91.4{\%}, freedom from distant metastasis 90.3{\%}, and overall survival 84.9{\%}, respectively. There were no Grade 4 acute or chronic radiation-related complications. Conclusions: Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications.",
author = "Chen, {Helen H.W} and Sen-Tien Tsai and Wang, {Mei Shu} and Yuan-Hua Wu and Wei-Ting Hsueh and Ming-Wei Yang and Yeh, {I. Chun} and Lin, {Jin Ching}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.ijrobp.2006.07.1385",
language = "English",
volume = "66",
pages = "1408--1414",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma

AU - Chen, Helen H.W

AU - Tsai, Sen-Tien

AU - Wang, Mei Shu

AU - Wu, Yuan-Hua

AU - Hsueh, Wei-Ting

AU - Yang, Ming-Wei

AU - Yeh, I. Chun

AU - Lin, Jin Ching

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC. Methods and Materials: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72%) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications. Results: All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences-3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively. There were no Grade 4 acute or chronic radiation-related complications. Conclusions: Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications.

AB - Purpose: Radiotherapy is the most effective treatment for nasopharyngeal carcinoma (NPC). The aim of this study is to evaluate the efficacy and toxicity of fractionated stereotactic body radiation therapy (SBRT) boost for NPC. Methods and Materials: Sixty-four patients with newly diagnosed, nonmetastatic NPC were treated with conventional radiotherapy 64.8-68.4 Gy followed by fractionated SBRT boost 12-15 Gy between January 2002 and July 2004. Most patients (72%) presented with Stage III-IV disease. Fifty-two patients also received cisplatin-based concurrent (38) or neoadjuvant (14) chemotherapy. The major endpoints were local control, overall survival, and complications. Results: All patients finished the planned dose of radiotherapy. After a median follow-up of 31 months (range, 22-54), 15 patients developed tumor recurrences-3 in the nasopharynx, 4 in the neck, 5 in distant sites, 1 in both nasopharynx and neck, 2 in the neck and a distant site. The 3-year actuarial rate of local control was 93.1%, regional control 91.4%, freedom from distant metastasis 90.3%, and overall survival 84.9%, respectively. There were no Grade 4 acute or chronic radiation-related complications. Conclusions: Fractionated SBRT boost for NPC is technically feasible and provides good local control without any severe complications.

UR - http://www.scopus.com/inward/record.url?scp=33751192889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751192889&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.07.1385

DO - 10.1016/j.ijrobp.2006.07.1385

M3 - Article

C2 - 17126207

AN - SCOPUS:33751192889

VL - 66

SP - 1408

EP - 1414

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -